Day: June 2, 2025

May 27, 2025 MONTHLY DISCLOSURE OF THE TOTAL NUMBER OF SHARES AND VOTING RIGHTS Articles L. 233-8 II of the Commercial Code and 223-16 of the General Regulation of the AMFDate   Shares   Voting rightsTheoretical* Exercisable**30 April 2025 43,203,225 48,744,994 48,315,187*This number is calculated on the basis of all the shares to which voting rights are attached, including shares which voting rights have been suspended, in accordance with Article 223-11 of the AMF general regulation related to the calculation of the crossing of thresholds with regard to the number of voting rights. **For information purposes, this number excludes the shares which voting rights have been suspended. The information is also available in the « Regulated Information » section of the Ipsos website: https://www.ipsos.com/en/regulated-informations/en....

VivoPower to leverage BitGo’s best-in-class OTC trading desk and custody platform to build digital asset treasury strategy NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) — BitGo, the leading infrastructure provider of digital asset solutions, and VivoPower International PLC (Nasdaq: VVPR, “VivoPower”), a publicly traded company that recently announced transition to an XRP focused treasury and decentralized finance solutions company, today announced a strategic partnership. VivoPower, having successfully raised US$121 million, will leverage BitGo as an exclusive over-the-counter (OTC) trading desk to acquire XRP for its initial US$100 million acquisition of XRP tokens. VivoPower will exclusively leverage BitGo for both the trading of its XRP holdings through BitGo’s 24/7/365 OTC trading desk and holding of its assets through BitGo’s best-in-class...

Nykredit Portefølje Administration A/S har anmodet Nasdaq Copenhagen om suspension af alle afdelinger, som administreres af Nykredit Portefølje Administration A/S. Det skyldes, at det grundet tekniske udfordringer ikke er muligt at stille korrekt NAV. Suspensionen vil blive ophævet, når det igen er muligt at stille korrekte priser. Følgende afdelinger er omfattet af suspensionen:Fund Name ISIN Order Book CodeAnsvarlig Defensiv DK0061671013 NBIBDKLAnsvarlig Moderat DK0061671286 NBIBMKLAnsvarlig Offensiv DK0061671369 NBIBOKLDefensiv KL DK0016188733 NBIDEKLModerat KL DK0016188816 NBIMOKLOffensiv KL DK0060441749 NBIOFKLEventuelle spørgsmål vedrørende denne meddelelse kan rettes til npa.pm@nykredit.dk eller Head of Portfolio Management & Operations, Christian Rye Holm CRH@nykredit.dk. Med venlig hilsen Nykredit...

NOT FOR DISTRIBUTION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW CALGARY, Alberta, June 02, 2025 (GLOBE NEWSWIRE) — Unless otherwise stated, all numbers in this press release are presented in Canadian dollars. Alaris Equity Partners Income Trust (“Alaris” or the “Trust“) (TSX: AD.UN) is pleased to announce that it has completed its previously announced offering of convertible unsecured senior debentures (“Debentures“) with a syndicate of underwriters (the “Underwriters“) led by National Bank Financial, CIBC Capital Markets and Desjardins Capital Markets, and including Acumen Capital Partners, Raymond James Ltd., RBC Capital Markets, Scotiabank, and Cormark Securities Inc. A total of $80 million aggregate...

Non-dilutive NIH funding supports development of MiNK’s allogeneic iNKT platform for immune regulation in high-risk HSCT settings NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced it has been awarded a grant from the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH). The grant will support development of MiNK’s allo-iNKT cell therapy platform for the prevention and treatment of graft-versus-host disease (GvHD) following hematopoietic stem cell transplantation (HSCT), in collaboration with the University of Wisconsin. “This non-dilutive funding from NIAID underscores the growing recognition...

One-time Amtagvi Treatment Continues to Show Deep, Durable Responses and Meaningful Survival One Third of Responses Remain Ongoing without Subsequent Treatment after Five Years Simultaneous Presentation at ASCO 2025 SAN CARLOS, Calif., June 02, 2025 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that the Journal of Clinical Oncology has published the final analysis from the Phase 2 C-144-01 clinical trial evaluating the individualized T cell therapy Amtagvi® (lifileucel) in patients with advanced melanoma. These five-year follow-up results are being simultaneously presented during an oral session today at the 2025 American...

ATHENS, Greece, June 02, 2025 (GLOBE NEWSWIRE) — OceanPal Inc. (NASDAQ: OP) (the “Company”), a global shipping company specializing in the ownership of vessels, today announced that, through a separate wholly-owned subsidiary, it has signed a Memorandum of Agreement to sell the 2004-built dry bulk vessel “Protefs” to a third party, for a sale price of US$7 million before commissions with delivery to the buyer no later than June 17, 2025. Upon completion of the aforementioned sale, OceanPal Inc.’s fleet will consist of 2 Panamax dry bulk vessels and an MR2 tanker vessel. A table describing the current OceanPal Inc. fleet can be found on the Company’s website, www.oceanpal.com. Information contained on the Company’s website does not constitute a part of this press release. About the Company OceanPal Inc. is a global provider of shipping...

Deployment Strengthens Company’s Position as Leading Provider of AI-Powered Screening Solutions for Critical InfrastructureShipment of another Sentinel Fixed Gantry CT underway — advancing AI-powered security screening across critical infrastructureShipment of another Sentinel Fixed Gantry CT underway — advancing AI-powered security screening across critical infrastructureShipment of another Sentinel Fixed Gantry CT underway — advancing AI-powered security screening across critical infrastructure Atlanta, GA, June 02, 2025 (GLOBE NEWSWIRE) — ScanTech AI Systems Inc. (the “Company” or “ScanTech AI”) (Nasdaq: STAI),  a leading innovator in advanced security screening technologies, today announced the successful delivery of its sixth Sentinel Fixed-Gantry CT system under a $3.5 million contract awarded...